Charles River Laboratories Intl. Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.34B), while Abrdn Physical Platinum Shares ETF trades at $15.33 (market cap $1.93B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 7.4× Abrdn Physical Platinum Shares ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| CRL | PPLT | |
|---|---|---|
Market Cap | $14.34B | $1.93B |
Volume | 1,242,136 | 2,947,556 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $310.77 | $25.23 |
52-Week Low | $149.93 | $13.73 |
Typical Hold Time | 33 Days | 42 Days |
Enterprise Value | $17.17B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 2.28% on the day, but maintains a bullish technical outlook with strong analyst support. The stock has consistently beaten earnings expectations in recent quarters, though profitability metrics show challenges with negative net income margins and ROE. Recent investor day presentations highlighted a refreshed growth strategy targeting 5-7% organic revenue growth and $300 million in cost savings by 2030, providing fundamental catalysts.
While CRL faces profitability headwinds and premium valuation multiples, strong analyst consensus (73% buy ratings) and a $305.50 price target suggest upside potential. Key risks include execution on margin improvement targets and ongoing cost volatility in non-human primate services. The combination of technical strength, strategic initiatives, and Wall Street support creates a favorable risk-reward profile for growth-oriented investors.
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →